Please delete the paragraph on page 1, lines 6-12.

In the Claims:

Please cancel claims 42 and 122-124 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

Please amend claim 198 as follows:

--198. (Amended) A method of treating depression in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a MCH1 antagonist, wherein:

(a) (1) the MCH1 antagonist does not inhibit the activity of central monoamine oxidase A greater than 50 percent, at a concentration of 10mM; and (2) the MCH1 antagonist does not inhibit the activity of central monoamine oxidase B greater than 50 percent, at a concentration of 10mM; and

(b) the MCH1 antagonist binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.--

Please add new claims 208-213 as follows:

--208. (New) A method of treating anxiety in a subject which comprises administering to the subject a composition

B7 Cont'd

comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a MCH1 antagonist, wherein the MCH1 antagonist binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.--

--209. (New) The method of claim 208, wherein the MCH1 antagonist also binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the human $5HT_{1A}$, human $5HT_{1B}$, human $5HT_{1D}$, human $5HT_{1E}$, human $5HT_{1F}$, human $5HT_{2A}$, rat $5HT_{2C}$, human $5HT_4$, human $5HT_6$ and human $5HT_7$ receptors.--

--210. (New) The method of claim 208, wherein the MCH1 antagonist also binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human histamine H_1 and H_2 receptors.--

--211. (New) The method of claim 208, wherein the MCH1 antagonist also binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human dopamine D_1, D_2, D_3, D_4 and D_5 receptors.--

--212. (New) The method of claim 208, wherein the MCH1 antagonist also binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human α_{1A}